Posted on

The latest on marijuana and autism across the globe

Podcast: Play in new window | Download

Subscribe: RSS

Since the ASF policy statement on marijuana for the treatment of ASD was published this summer, there have been some new scientific studies that may be of interest to families.  As it turns out CBD has opposite effects in the brains of people with autism compared to those without autism, meaning that it is absolutely essential that more research is done specifically in people across the spectrum in ASD.  Also, early studies in Israel and Brazil are showing some positive effects on behavior, but they are open label non controlled compassionate use basis studies, which in encouraging, but the science needs to be more rigorous and more studies need to be done in people with autism using standardized autism assessments if any progress is to be made.  Luckily a new study at NYU is enrolling for just that approach.  Please contact Latoya.King@nyulangone.edu if you want to learn more about that.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732821/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784992/

https://www.ncbi.nlm.nih.gov/pubmed/31736860

https://www.ncbi.nlm.nih.gov/pubmed/30382443

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336869/

 

 

Posted on

INSAR with a T, for “technology”

Podcast: Play in new window | Download

Subscribe: RSS

Lots of news outlets have great summaries of things that were presented at the International Society for Autism Research. However, one area was relatively missed:  technology.    This week’s podcast summarizes advances in technology for people with autism, how they are being used, what they could be used for and how they will improve services and help for those on the spectrum.  They range from ways to aid diagnosis, to better understanding of features and symptoms in different settings, to improved intervention.

Posted on

Can IGF-1 treat autism symptoms? A clinical trial aims to find out

Podcast: Play in new window | Download

Subscribe: RSS

A full transcript of this podcast episode can be read on the ASF blog here.

Researchers at Mount Sinai led by Alex Kolevzon are running a clinical trial of the compound insulin-like growth factor 1 (IGF-1) for children with idiopathic autism. Dr. Kolevzon’s team previously demonstrated the safety and feasibility of IGF-1 in treating Phelan-McDermid syndrome, a single-gene form of autism. Particularly, the IGF-1 treatment improved symptoms of social impairment and repetitive behaviors, which are core symptoms of autism. Expanding their investigation into idiopathic autism, the researchers are working hard to make sure families can comfortably and knowledgeably participate in the clinical trial. Mahir Rahman spoke with Dr. Kolevzon about the study and where it hopes to go. Interested in joining the study? Go here to learn more.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326443/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450831/

Posted on

Clinical trials talk with Tom Frazier from Autism Speaks

Podcast: Play in new window | Download

Subscribe: RSS

This week, a special surprise:  a conversation with Dr. Thomas Frazier, Chief Science Officer of Autism Speaks, on what is needed for better clinical trials for drug treatments for ASD, and what they are going to be doing to help move the science along.  Of course, the conversation hit on other topics, like disclosure of a diagnosis, sex differences, and some of the newest more exciting findings in autism research.